[Rituximab in the treatment of diffuse large B-cell lymphoma: The CACNA1C subunit of channel Cav1.2 expression linked to certain forms of resistance]

Med Sci (Paris). 2021 Apr;37(4):406-408. doi: 10.1051/medsci/2021043. Epub 2021 Apr 28.

[Article in French]

Authors

Sonia Bouabdallah¹, Mohamed Lamine Mariko¹, Jeremy Besson¹, Olivier Dellis²

Affiliations

¹ M1 Biologie Santé, Université Paris-Saclay, 91405 Orsay, France.
² Inserm U1193 Physiopathologie et traitement des maladies du foie, Université Paris-Saclay, France.

PMID: 33908862
DOI: 10.1051/medsci/2021043

No abstract available

Publication types

News

MeSH terms

Antineoplastic Agents, Immunological / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Calcium Channels, L-Type / metabolism*
Cyclophosphamide / therapeutic use
Doxorubicin / therapeutic use
Drug Resistance, Neoplasm*
Humans
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Lymphoma, Large B-Cell, Diffuse / metabolism
MicroRNAs / metabolism*
Prednisone / therapeutic use
Rituximab / therapeutic use
Vincristine / therapeutic use

Substances

Antineoplastic Agents, Immunological
CACNA1C protein, human
Calcium Channels, L-Type
MIRN363 microRNA, human
MicroRNAs
R-CHOP protocol
Rituximab
Vincristine
Doxorubicin
Cyclophosphamide
Prednisone